What is thymalin made from?

It is extracted from calf thymus. It is a preparation rather than a defined molecule, which means its composition depends on how it was made — a real difference from the synthesised peptides in this catalogue.

Has thymalin been studied independently?

Very little. Nearly all of the published work comes from the institute that developed it, including the most striking claims. Independent replication is what turns a finding into established knowledge, and it is largely absent here.

Why is the thymus the target?

Because it is where T-cells mature and it shrinks steadily with age. That involution is well documented and is the premise the preparation was built on — the premise is sound even where the evidence for the preparation is thin.

Is thymalin an approved medicine?

It has been used clinically in Russia. It holds no marketing authorisation in the EU, UK or US, and is supplied here as a laboratory reagent for research use only.

Is thymalin the same as thymosin alpha-1?

No. Thymosin alpha-1 is a defined synthetic peptide with its own literature. Thymalin is a thymic extract containing multiple fractions, and the two should not be treated as interchangeable.

Research guides

Thymalin: what the research says

A calf thymus extract rather than a defined molecule, with a literature that comes almost entirely from the institute that developed it. Why that matters.

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

THYMALIN
Immune & Anti-Inflammatory

Two facts shape how everything else about this preparation should be read, and both belong before any finding: it is an extract rather than a single molecule, and its literature originates almost entirely from one research programme.

What the preparation is

A peptide preparation extracted from calf thymus, developed in the 1970s at the Institute of Gerontology in what was then the Soviet Union. Because it is an extract, its composition depends on the preparation rather than being fixed by a sequence — a fundamental difference from the synthesised peptides elsewhere in this catalogue, and one that makes batch-to-batch comparability a real question rather than a theoretical one.

A dipeptide, L-Glu-L-Trp, was isolated from it as one active fraction, which is the closest the work comes to identifying a defined molecule responsible for the reported activity.

The biological rationale

The thymus is where T-cells mature, and it involutes steadily with age. That is a real and well-documented phenomenon, and it is the premise the preparation was built on. Published work from the originating group reports effects on T-cell differentiation, on recognition of peptide–MHC complexes, and on cytokine release from blood lymphocytes.

The provenance problem

Independent replication is the mechanism by which a finding becomes established knowledge, and this literature has had very little of it. The most striking published claims — including a long-term human study reporting effects on survival — come from the same institute that developed the preparation. That is not an accusation; a preparation developed and championed by one institute will naturally have a literature dominated by it. But it means the volume of publication is a weaker signal here than it would be for a compound studied by many groups, and a reader should weight it accordingly.

This is the same structural caveat that applies to BPC-157 and to Epitalon, and for the same reason. Where nearly all the evidence for a compound comes from its originators, the absence of contradicting results is not independent confirmation.

What studies reported

Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.

Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.

Morozov & Khavinson (1997)International Journal of Immunopharmacology · 19(9-10):501–5
Reported that natural and synthetic thymic peptides activated T-cell differentiation and altered cytokine excretion of blood lymphocytes.
in vitro and human clinical use Source
Khavinson et al. (2003)Neuroendocrinology Letters · 24(3-4):233–40
Reported long-term follow-up of older participants given thymic and pineal peptide preparations, examining survival over the observation period. Published by the institute that developed the preparations.
human, long-term follow-up Source

Adverse and null findings reported

No dedicated safety study has been published for this compound. That is not a finding that none exists — it means the question has not been asked in print, and the gaps below say so.

What the research does not establish

An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.

The `adverse` list is empty because no independent safety study of this preparation has been published — not because it has been examined and found harmless. Given that nearly all the efficacy literature comes from the originating group, the absence of reported harm is particularly weak evidence here.
The preparation is an extract, so composition varies between batches and manufacturers. A finding from one preparation is not automatically a finding about another sold under the same name.
No randomised controlled trial of thymalin conducted by an independent group has been published, and it holds no marketing authorisation in the EU, UK or US.
The long-term human study reporting survival effects is a striking claim from the developing institute that has not been independently replicated. Extraordinary claims from a single source are exactly where independent replication matters most.
The mechanism is described at the level of what thymic peptides do to lymphocytes in culture. How the extract as supplied relates to those fractions is not established.

Common questions

What is thymalin made from?: It is extracted from calf thymus. It is a preparation rather than a defined molecule, which means its composition depends on how it was made — a real difference from the synthesised peptides in this catalogue.
Has thymalin been studied independently?: Very little. Nearly all of the published work comes from the institute that developed it, including the most striking claims. Independent replication is what turns a finding into established knowledge, and it is largely absent here.
Why is the thymus the target?: Because it is where T-cells mature and it shrinks steadily with age. That involution is well documented and is the premise the preparation was built on — the premise is sound even where the evidence for the preparation is thin.
Is thymalin an approved medicine?: It has been used clinically in Russia. It holds no marketing authorisation in the EU, UK or US, and is supplied here as a laboratory reagent for research use only.
Is thymalin the same as thymosin alpha-1?: No. Thymosin alpha-1 is a defined synthetic peptide with its own literature. Thymalin is a thymic extract containing multiple fractions, and the two should not be treated as interchangeable.

Compounds covered

The reference page for each compound this article discusses.

Thymalin

Epitalon (Epithalon, AEDG): what the research says
A tetrapeptide investigated for telomerase activity, with a literature long dominated by one institute — and a recent independent replication worth reading.
BPC-157: what the research says
Body Protection Compound 157 has a large rodent literature and almost no human data. What the studies measured, in which models, and the caveat behind them.
Peptide shelf life and stability
How long lyophilised and reconstituted peptides keep, and the four things that shorten it: temperature, moisture, light and oxidation. Storage figures included.

About this article

Everything reported here comes from published research, and each finding names the model the study used — cell culture, rat, or human. Findings in one model do not transfer to another, most of the work described is preclinical, and none of it is a claim that a compound is safe or effective for any purpose. Nothing on this page describes doses, routes of administration, or use in a person.

Approval status varies by compound and by country. A few of the substances described are the active ingredient of medicines authorised in the EU; most have no marketing authorisation anywhere and have never been assessed by a regulator. Neither is supplied as a medicine here. All material supplied by ASSAY is sold for in-vitro laboratory research only, and is not a drug, food, cosmetic or medical device, and not for human or veterinary use.

All guides